Targets › IGG
1 program from 1 company in 1 trial: 1 Phase 3; Respiratory; next expected readout Jul 2028.
Open in Phaseline: the race on IGG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Biotest | Trimodulin (BT588) Polyclonal immunoglobulin preparation (IgG, IgM, IgA) | IGG, IGM, IGA | Phase 3 | Community-acquired Pneumonia | Jul 2028 |
Community-acquired Pneumonia (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.